Compare McKesson Corporation (MCK) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Tango Therapeutics Inc. — how do they compare? McKesson Corporation trades at $986 (market cap $113.86B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: McKesson Corporation is far larger — about 30.4× Tango Therapeutics Inc.'s market cap, and McKesson Corporation pays a 0.39% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Tango Therapeutics Inc. for 0 Days on average.
| MCK | TNGX | |
|---|---|---|
Market Cap | $113.86B | $3.74B |
Volume | 767,917 | 3,438,781 |
Sector | Health | Health |
52-Week High | $995.69 | $32.90 |
52-Week Low | $725.17 | $7.50 |
Typical Hold Time | 74 Days | 0 Days |
Enterprise Value | $120.40B | $2.76B |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCK trades at $961.88, up 0.64% today, showing strong momentum with three consecutive earnings beats and a bullish technical outlook. The stock benefits from robust revenue growth reaching $359.1B in 2025 and positive sentiment from the recent CVS Health partnership extension through 2032. Analyst consensus remains strongly bullish with 81% buy ratings and a $956.43 price target, though the current price slightly exceeds this target.
MCK presents a compelling investment case with solid fundamentals and growth trajectory, though investors should monitor margin pressures and competitive dynamics. The company's strong cash flow generation and institutional support provide stability, while technical indicators suggest near-term resistance around $967-$978 levels could limit immediate upside potential.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
